News Releases

-- Treatment with olvimulogene nanivacirepvec (Olvi-Vec)-primed immunochemotherapy shows objective response and progression-free survival clinical benefits well exceed historical comparisons and patients' own last prior therapy -- The majority of patients benefited from apparent reversal of

Distinguished Gynecologic Oncology Experts to Guide Olvi-Vec Development Efforts SAN DIEGO, June 4, 2020 /PRNewswire/ -- Genelux Corporation, a privately-held, clinical-stage immuno-oncology company, today announced that it has formed a Clinical Advisory Board (CAB) on gynecologic cancers that will

Continues Preparation of Registrational Trial of Olvi-Vec in the Treatment of Platinum-Refractory/Resistant Ovarian Cancer Patients SAN DIEGO, May 7, 2020 /PRNewswire/ -- Genelux Corporation, a privately-held, clinical-stage immunotherapy company, today announced the outcome of a Type C meeting